Details of the Drug Combinations

General Information of This Drug (ID: DMQM2FH)

Drug Name

RRx-001 DMQM2FH

Synonyms

RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 3	[1]
Lymphoma	2A80-2A86	Phase 2	[2]
Neuroendocrine cancer	2B72.1	Phase 2	[3]
Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
Ovarian epithelial cancer	2C73	Phase 2	[3]
Anaplastic glioma	2A00.0	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Irinotecan + RRx-001	DCEYRQ1	Irinotecan	Malignant Solid Tumor	[4]
Irinotecan + RRx-001	DCVMTYU	Irinotecan	Colorectal Neoplasms	[5]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03699956) RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02452970) RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT02801097) RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
5	ClinicalTrials.gov (NCT02096354) A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer